ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NYMX Nymox Pharmaceutical Corp

0.20
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nymox Pharmaceutical Corp NASDAQ:NYMX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.20 0.2003 0.2169 0 01:00:00

EQUITY ALERT: Rosen Law Firm Reminds Nymox Pharmaceutical Corporation Investors of Important Class Action Deadline -- NYMX

12/12/2014 9:04pm

GlobeNewswire Inc.


Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Nymox Pharmaceutical Charts.

The Rosen Law Firm reminds purchasers of Nymox Pharmaceutical Corporation common stock (Nasdaq:NYMX) during the period from January 31, 2011 through November 2, 2014, of the important January 26, 2015 lead plaintiff deadline in the class action.

To join the Nymox class action, go to the website http://www.rosenlegal.com/cases-447.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

The lawsuit asserts that Nymox failed to disclose material information affecting the Phase 3 clinical trials for Nymox's proprietary drug NX-1207 for the treatment of benign prostatic hyperplasia (BPH). Specifically, the Complaint alleges that Nymox misled investors by misrepresenting or concealing: (1) that the Phase 3 trial results were not objective; (2) the difficulty in obtaining objective and measured results, (3) the small likelihood of enrolling sufficient patients for the trial; and (4) the trial had an unreasonably small chance of success.

On November 2, 2014, Nymox disclosed that its two Phase 3 studies of NX-1207 were halted because the drug failed to meets its primary endpoints for efficacy. On November 3, 2014, Nymox held an investor conference call in which it admitted it was aware of certain problems concerning the Phase 3 trials. As a result of this adverse information, Nymox's share price dropped over $4.0/share or more than 80%, damaging investors.

If you wish to join the class action at no cost go to http://www.rosenlegal.com/cases-447.html or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

CONTACT: Laurence Rosen, Esq.
         Phillip Kim, Esq.
         Jonathan Horne, Esq.
         The Rosen Law Firm P.A.
         275 Madison Avenue, 34th Floor
         New York, NY 10016
         Tel: (212) 686-1060
         Toll Free: (866) 767-3653
         Fax: (212) 202-3827
         lrosen@rosenlegal.com
         pkim@rosenlegal.com
         jhorne@rosenlegal.com
         www.rosenlegal.com

1 Year Nymox Pharmaceutical Chart

1 Year Nymox Pharmaceutical Chart

1 Month Nymox Pharmaceutical Chart

1 Month Nymox Pharmaceutical Chart

Your Recent History

Delayed Upgrade Clock